Observation On Curative Effect Of Shen Song Yang Xin Capsule Combined With Betaloc On Heart Failure With Ventricular Contraction

Objective:Through observation on shensongyangxin capsule combined with betaloc on mild to moderate chronic cardiac insufficiency with premature ventricular contraction of the efficacy and improvement of clinical symptoms in patients, to evaluate the efficacy of the two drugs combination in the treatment.Material and method:1.Selected March 2014–December 2014 in hospitalized patients of the Liaoning Provincial people’s Hospital, Department of Cardiology(n=60, male=29, female=31, 49-74 years of age.), randomized, sequential divided into two groups. 2.Inclusion criteria: diagnosed with mild to moderate chronic heart failure with premature ventricular contractions, cardiac functionⅡ-Ⅲ, 24-hour Holter confirmed the existence of total PVCs >720 times. 3. Experiment group for Shensongyangxin capsule combined with betaloc treatment group, n=30, M=14, F=16, age51-74 years, given betaloc 12.5mg-25 mg / times, 2 times / day oral treatment and Shensongyangxin capsule 4/times, 3times / day oral treatment, control group betaloc treatment group, n= 30, M=15, F=15, given betaloc 12.5 mg-25 mg times, 2 times / day oral treatment, treatment for 12 weeks. Before and after treatment were collected the total number of PVCs in 24-hour Holter and TCM symptom score, observe and record whether there are adverse events. Observed whether total number of PVC and syndrome of TCM changed.RESULTS:1. General information: General information on the two groups has not statistically significant difference(P>0.05). 2. Total number of PVCs before and after treatment: the number of PVCs in the experimental group and the control group has been reduced. Before treatment,the experimental group’s average number of PVCs is 1358.97±520.2, averages of PVCs after medication is 555.97±333.29, an average reduction of 803.00±497.70 times after treatment. Before treatment in the control group average total number of PVCs is 1493.20±576.13 times, the averaged total number of PVCs after treatment is 1143.27±790.66 times, an average reduction of 350.07±381.37 times after treatment. PVCs’ reduction in experiemental group is more than control group’s. 3. TCM symptom score: TCM symptom scores of experimental group and control group before and after treatment were decreased compared with the previous. experimental group average scores was 24.8±11.89 before treatment, after treatment was 7.6±7.07. Control group mean score was 26.8±12.94 before treatment, after treatment was 19.9±17.35. 4. During the experiment, there was no significant adverse drug reactions.Conclusion:1. Shensongyangxin capsule combined with metoprolol treatment can effectively reduce the PVCs of chronic cardiac insufficiency patients 2. Shensongyangxin capsule combined with betaloc in the treatment can improve the palpitation, chest tightness, fatigue, insomnia, five frustrating heat, etc of TCM symptom. 3. Shensongyangxin capsule combined with betaloc in the treatment of chronic cardiac insufficiency patients with PVCs, the treatment effect is better than the simple application of metoprolol treatment. 4. No significant drug adverse reactions, clinical application is safe.